• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

天然C1与单体免疫球蛋白及C1抑制剂相互作用的演示

Demonstration of the interaction of native C1 with monomeric immunoglobulins and C1 inhibitor.

作者信息

Ziccardi R J

出版信息

J Immunol. 1985 Apr;134(4):2559-63.

PMID:3973388
Abstract

The association of native C1 with physiologically relevant proteins was studied by ultracentrifugation. 125I-C1 was centrifuged through numerous sucrose density gradients, each of which contained a different concentration of monomeric (19S) IgM throughout the gradient. The s-rate of C1 (16S) increased with increasing IgM input to a maximum of 32S. In the absence of C1q, the C1r2s2 subunit did not bind to the Ig. In gradients containing physiologic concentrations of IgM (1.3 mg/ml) at 0.14 M ionic strength, the observed s-rate of C1 was 21S. In the presence of 13 mg/ml IgG, C1 sedimented with an s-rate of 19S. Thus, under physiologic conditions, a significant fraction of native C1 is reversibly bound to monomeric Ig. SDS-PAGE analyses show that this interaction does not lead to C1 activation. The interaction of native C1 with C1 inhibitor (C1-In) was studied by ultracentrifugation at physiologic ionic strength. Purified 125I-C1-In alone sedimented with an s-rate of 4S. However in the presence of excess native C1, one-third of the C1-In co-sedimented with C1 at a 16S position. For these studies, 100 microM nitrophenylguanidinobenzoate (NPGB) was present throughout the sucrose density gradient to prevent C1 activation during centrifugation. As the concentration of NPGB was increased, the percent of 125I-C1-In at 16S decreased, indicating that C1-In was binding (reversibly) to the C1 active site region(s), which is at least partially accessible in uncleaved C1. In controls, when NPGB was omitted or activated C1 was used, the s-rate of 125I-C1-In was only 12S due to the release of C1rC1s(C1-In)2 from activated C1. Thus, under physiologic conditions native C1 is reversibly bound to C1-In.

摘要

通过超速离心研究天然C1与生理相关蛋白的关联。将125I-C1通过多个蔗糖密度梯度进行离心,每个梯度在整个梯度中含有不同浓度的单体(19S)IgM。C1(16S)的沉降速率随着IgM输入量的增加而增加,最大可达32S。在缺乏C1q的情况下,C1r2s2亚基不与Ig结合。在离子强度为0.14M、含有生理浓度IgM(1.3mg/ml)的梯度中,观察到的C1沉降速率为21S。在存在13mg/ml IgG的情况下,C1以19S的沉降速率沉降。因此,在生理条件下,相当一部分天然C1与单体Ig可逆结合。SDS-PAGE分析表明这种相互作用不会导致C1激活。在生理离子强度下通过超速离心研究天然C1与C1抑制剂(C1-In)的相互作用。纯化的125I-C1-In单独沉降时沉降速率为4S。然而,在存在过量天然C1的情况下,三分之一的C1-In在16S位置与C1共沉降。对于这些研究,在整个蔗糖密度梯度中都存在100μM硝基苯基胍苯甲酸酯(NPGB),以防止离心过程中C1激活。随着NPGB浓度的增加,16S处125I-C1-In的百分比降低,表明C1-In正在(可逆地)与C1活性位点区域结合,该区域在未裂解的C1中至少部分可及。在对照中,当省略NPGB或使用活化的C1时,由于从活化的C1中释放出C1rC1s(C1-In)2,125I-C1-In的沉降速率仅为12S。因此,在生理条件下天然C1与C1-In可逆结合。

相似文献

1
Demonstration of the interaction of native C1 with monomeric immunoglobulins and C1 inhibitor.天然C1与单体免疫球蛋白及C1抑制剂相互作用的演示
J Immunol. 1985 Apr;134(4):2559-63.
2
The relationship between the binding ability and the rate of activation of the complement component C1.补体成分C1的结合能力与激活速率之间的关系。
Immunology. 1980 Sep;41(1):179-85.
3
The first component of complement. I. Purification and properties of native C1.补体的第一成分。I. 天然C1的纯化及特性
J Immunol. 1980 Jul;125(1):390-5.
4
Nature of the interaction between the C1q and C1r2S2 subunits of the first component of human complement.人类补体第一成分的C1q与C1r2S2亚基之间相互作用的性质
Mol Immunol. 1985 Apr;22(4):489-94. doi: 10.1016/0161-5890(85)90133-6.
5
Activation of human C1: analysis with Western blotting reveals slow self-activation.人C1的激活:蛋白质印迹分析显示其存在缓慢的自我激活。
J Immunol. 1987 Sep 1;139(5):1602-8.
6
Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism.人类补体第一成分(C1)通过分子内自催化机制的自发激活。
J Immunol. 1982 Jun;128(6):2500-4.
7
Role for the third constant domain of the IgG H chain in activation of complement in the presence of C1 inhibitor.在存在C1抑制剂的情况下,IgG重链的第三个恒定结构域在补体激活中的作用。
J Immunol. 1989 Jan 1;142(1):195-201.
8
Influence of aggregate size on the binding and activation of the first component of human complement by soluble IgG aggregates.聚集体大小对可溶性IgG聚集体与人补体第一成分的结合及激活的影响。
Immunology. 1982 Apr;45(4):705-13.
9
The role of immune complexes in the activation of the first component of human complement.免疫复合物在人补体第一成分激活中的作用。
J Immunol. 1984 Jan;132(1):283-8.
10
Reconstitution of C1 in native proenzyme form and its use in a quantitative C1 activation test.
J Immunol. 1977 Nov;119(5):1664-7.

引用本文的文献

1
Pharmaceutical Machine Learning: Virtual High-Throughput Screens Identifying Promising and Economical Small Molecule Inhibitors of Complement Factor C1s.药物机器学习:虚拟高通量筛选鉴定有前景且经济的补体因子 C1s 小分子抑制剂。
Biomolecules. 2018 May 7;8(2):24. doi: 10.3390/biom8020024.
2
Paths reunited: Initiation of the classical and lectin pathways of complement activation.途径重连:经典途径和补体激活的凝集素途径的启动。
Immunobiology. 2010;215(1):1-11. doi: 10.1016/j.imbio.2009.08.006. Epub 2009 Sep 27.
3
Anti-inflammatory effects of C1-Inhibitor in porcine and human whole blood are independent of its protease inhibition activity.
C1 抑制剂在猪和人全血中的抗炎作用与其蛋白酶抑制活性无关。
Innate Immun. 2010 Aug;16(4):254-64. doi: 10.1177/1753425909340420. Epub 2009 Aug 26.
4
Biological activities of C1 inhibitor.C1抑制剂的生物学活性。
Mol Immunol. 2008 Oct;45(16):4057-63. doi: 10.1016/j.molimm.2008.06.028. Epub 2008 Jul 31.
5
Complement 1 inhibitor is a regulator of the alternative complement pathway.补体1抑制剂是替代补体途径的一种调节因子。
J Exp Med. 2001 Dec 3;194(11):1609-16. doi: 10.1084/jem.194.11.1609.
6
C1 inhibitor removes the entire C1qr2s2 complex from anti-C1Q monoclonal antibodies with low binding affinities.C1 抑制剂可从结合亲和力较低的抗 C1Q 单克隆抗体中去除整个 C1qr2s2 复合物。
Immunology. 1998 Dec;95(4):648-54. doi: 10.1046/j.1365-2567.1998.00635.x.
7
Mechanism of action of anti-C1-inhibitor autoantibodies: prevention of the formation of stable C1s-C1-inh complexes.抗C1抑制物自身抗体的作用机制:阻止稳定的C1s-C1抑制物复合物的形成。
Mol Med. 1998 Feb;4(2):119-28.
8
Angioedema induced by a peptide derived from complement component C2.由补体成分C2衍生的一种肽引起的血管性水肿。
J Exp Med. 1988 Nov 1;168(5):1685-98. doi: 10.1084/jem.168.5.1685.